Company overview
Basic information
Company name
Antigenas, UAB
Company code
302518539
VAT code
LT100008529612
Registered address
Vilniaus r. sav., Zujūnų sen., Zujūnų k., Vilties g. 22, LT-14163
Registration date
2010-06-02
Company age: 16 y. 3 mo.
Contact information
Edit data
Phone
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
https://www.vetgyd.lt
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
Veterinary activities
Ownership form
Private without foreign capital
UAB "Antigenas"
Company code: 302518539
Address: Vilniaus r. sav., Zujūnų sen., Zujūnų k., Vilties g. 22, LT-14163
VAT code: LT100008529612
Download a detailed company report
Make confident decisions with all the information about Antigenas, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.
Description
This description was generated by artificial intelligence.
Antigenas, UAB (company code 302518539) is an operational private limited liability company registered on 2 June 2010. It belongs to the sector of national private non-financial companies and is classified as a micro company under private ownership, with Lithuanian natural and legal persons holding more than 50% of the authorised capital and no foreign investor capital. The governance structure is listed as CEO only. The company’s registered office is in Zujunu k., Zujunu sen., Vilniaus r. sav., Vilniaus county.
The company operates in EVRK activity N.75.00.00, Veterinary activities. Its share capital is €2.9K. Financially, Antigenas generated revenue of €82.5K in 2025, up 12.0% year on year and 9.5% over two years. Despite the increase in sales, the company recorded a net loss of €2.5K in 2025, with a profit margin of -3.0%. Equity stood at €20.7K and total assets at €24.6K, while liabilities were €3.6K. The company remained asset-light, with an asset turnover of 3.35x. Average employment was 3 in 2023, 3 in 2024 and 3 in 2025, and so far in 2026 it averaged 2 employees.
The company operates in EVRK activity N.75.00.00, Veterinary activities. Its share capital is €2.9K. Financially, Antigenas generated revenue of €82.5K in 2025, up 12.0% year on year and 9.5% over two years. Despite the increase in sales, the company recorded a net loss of €2.5K in 2025, with a profit margin of -3.0%. Equity stood at €20.7K and total assets at €24.6K, while liabilities were €3.6K. The company remained asset-light, with an asset turnover of 3.35x. Average employment was 3 in 2023, 3 in 2024 and 3 in 2025, and so far in 2026 it averaged 2 employees.